Xtandi 40 MG tablet 120S
Ended Awarded
- Contract number
- SPE2DX25F6XUM
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Obligated
- $8,339
Award facts
- Contract value 100% obligated
- $8,339.18 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency's Medical Supply Chain on September 25, 2025, for the supply of Xtandi 40 mg tablets (120-count units). The contract carries no set-aside designation and is scheduled for completion by September 26, 2025, with performance taking place at the vendor's Park Ridge facility. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499,999,999 vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting Department of Defense medical facilities worldwide.
Xtandi is a prescription oncology medication used in the treatment of prostate cancer, reflecting DMS Pharmaceutical Group's established role as a critical supplier of specialized pharmaceutical products to military healthcare systems. The company has consistently leveraged its woman-owned small business status to compete effectively in federal procurement markets, maintaining a robust portfolio of contract awards across branded and generic prescription drugs, biologics, and medical consumables. This award demonstrates the vendor's continued integration into the federal pharmaceutical supply chain and the DLA's reliance on DMS Pharmaceutical Group for delivering essential medications to Department of Defense healthcare facilities.
Quick answers
Who was awarded contract SPE2DX25F6XUM?
SPE2DX25F6XUM was awarded to DMS Pharmaceutical Group Inc. by Medical Supply Chain (Troop Support) on September 25, 2025.
How much is contract SPE2DX25F6XUM worth?
The government has obligated $8,339 on SPE2DX25F6XUM.
Is contract SPE2DX25F6XUM an order under another contract?
Yes. SPE2DX25F6XUM is a delivery order under SPE2DX15D9168, an indefinite delivery contract.
Was contract SPE2DX25F6XUM competed?
The extent of competition for SPE2DX25F6XUM was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award